Viatris (VTRS) Competitors

Viatris (NASDAQ:VTRS) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Is VTRS or PFE more profitable?

Pfizer has a net margin of 12.62% compared to Viatris' net margin of -26.45%. Pfizer's return on equity of 20.33% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-26.45%	16.20%	7.01%
Pfizer	12.62%	20.33%	8.53%

Do analysts recommend VTRS or PFE?

Viatris presently has a consensus target price of $10.40, suggesting a potential upside of 14.04%. Pfizer has a consensus target price of $28.55, suggesting a potential upside of 11.31%. Given Viatris' higher probable upside, equities analysts clearly believe Viatris is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Pfizer	1 Sell rating(s)	13 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.45

Is VTRS or PFE a better dividend stock?

Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 5.3%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.7%. Viatris pays out -15.1% of its earnings in the form of a dividend. Pfizer pays out 124.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has raised its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Do institutionals and insiders hold more shares of VTRS or PFE?

79.9% of Viatris shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 0.1% of Viatris shares are owned by company insiders. Comparatively, 0.1% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has more volatility and risk, VTRS or PFE?

Viatris has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.

Does the media favor VTRS or PFE?

In the previous week, Pfizer had 105 more articles in the media than Viatris. MarketBeat recorded 108 mentions for Pfizer and 3 mentions for Viatris. Viatris' average media sentiment score of 0.79 beat Pfizer's score of 0.76 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pfizer	49 Very Positive mention(s)	12 Positive mention(s)	32 Neutral mention(s)	4 Negative mention(s)	7 Very Negative mention(s)	Positive

Which has preferable earnings & valuation, VTRS or PFE?

Pfizer has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.74B	0.73	-$634.20M	-$3.17	-2.88
Pfizer	$63.63B	2.29	$8.03B	$1.38	18.59

Summary

Pfizer beats Viatris on 14 of the 20 factors compared between the two stocks.